PURE Bioscience, Inc.
corporate_fare Company Profile
PURE Bioscience, Inc. (OTC:PURE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for PURE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-15, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for PURE spans 10-Q, 8-K.
Recent high-impact activity:
- PURE Bioscience Q3 Net Loss Widens to $624K on $506K Revenue
- PURE Bioscience Reports Increased Q3 Loss, Raises $1M in Dilutive Private Placement, and Authorizes 92% More Shares
- PURE Bioscience Reports Q3 Results with Surging Current Debt and CEO Transition
- PURE Bioscience Secures $1.0M in Dilutive Private Placement at Discounted Price
- PURE Bioscience Secures $1.0M Private Placement, Directors Invest Heavily Amidst Going Concern Warning
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 16,734 shares in PURE as of the September 15, 2026 settlement, a 9.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 20.1% of PURE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PURE, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.
Going Concern Warning · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →